出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年4月
Vaccines Market – Global Forecast To 2029
ワクチン市場 : 技術（複合体、組換え体、弱毒化生、トキソイド、ウイルスベクター、mRNA）、種類（1価、多価）、疾患（肺炎球菌、インフルエンザ、HPV、帯状疱疹、MMR、ロタウイルス、RSV）、投与経路 – 2029年までの世界予測
Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration – Global Forecast to 2029
| ページ数 | 402 |
| 図表数 | 451 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレートライセンス | USD 8,150 |
| エンタープライズサイトライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
[myphp file=”contact”] 出版社・価格・納期について
Report Overview
The vaccines market (including COVID-19 vaccines) is projected to reach USD 94.9 Billion by 2029 from USD 78.0 Billion in 2024, at a CAGR of 4.0% during the forecast period.
ワクチン市場（新型コロナウイルス感染症ワクチンを含む）は、予測期間中のCAGR 4.0％で、2024年の780億ドルから2029年までに949億ドルに達すると予測されています。
Similarly the vaccines market (excluding COVID-19 vaccines) is projected to reach USD 80.3 Billion by 2029 from USD 53.0 Billion in 2024, at a CAGR of 8.7% during the forecast period. The vaccines market is driven by several key factors, including increasing global population, rising prevalence of infectious diseases, and growing awareness of preventive healthcare. Technological advancements in vaccine development, coupled with expanding immunization programs worldwide, contribute to market growth.
“The conjugate vaccines segment (excluding COVID -19 vaccines) held the dominant share in the vaccines market.”
Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, conjugate vaccines and other vaccines. Conjugate vaccines segment dominated the vaccine market in 2023. Robust research and development investments, strategic partnerships, and favorable regulatory environments have further bolstered the prominence of conjugated vaccines, solidifying their position as indispensable tools in the fight against infectious diseases and driving sustained growth in the vaccines market.
“HPV segment (excluding COVID-19 vaccines) accounted for the largest share of the disease indication segment in 2023.”
Based on disease indication, the vaccines market (excluding COVID-19 vaccines) is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, RSV, and other disease indications. In 2023, HPV segment dominated the vaccines market. RSV segment is anticipated to grow at significant CAGR during the forecast period of 2024-2028 owing to various factors such as launch of new HPV vaccine and robust products under clinical trials.
“Asia Pacific region is likely to grow at a faster pace in the vaccines market (excluding COVID -19 vaccines).”
The vaccines market (excluding COVID-19 vaccines) region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. The Asia-Pacific region is poised to experience significant growth in the vaccines market due to several key factors such as increasing healthcare expenditure in countries like China, India, and Southeast Asian nations are driving demand for vaccines to combat infectious diseases. Expanding government initiatives aimed at improving vaccination coverage and healthcare infrastructure further stimulate market growth.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%, and Demand Side – 20%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-4% and Africa -1%
List of Companies Profiled in the Report:
• GSK plc (UK)
• Merck & Co., Inc. (US)
• Pfizer, Inc. (US)
• Sanofi (France)
• CSL (Australia)
• Emergent (US)
• Johnson & Johnson Services Inc. (US)
• AstraZeneca (UK)
• Serum Institute of India Pvt. Ltd. (India)
• Bavarian Nordic (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Panacea Biotec (India)
• Biological E. Limited (India)
• Bharat Biotech (India)
• Novavax (US)
• Inovio Pharmaceuticals (US)
• Sinovac (China)
• Incepta Pharmaceuticals (Bangladesh)
• Valneva SE (France),
• VBI Vaccines Inc. (US)
• Bio Farma (Indonesia)
• FSUE NPO Microgen (Russia)
• Zhi fei Biological (China)
• Indian Immunologicals Ltd (India)
Research Coverage:
This report provides a detailed picture of the vaccine market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, government support and funding for vaccine development), restraints (High cost of vaccine development), opportunities (Rising focus on therapeutic vaccines, Extensive R&D for vaccines and increased investments in clinical trials) and challenges (stringent regulatory processes, product recall) are influencing the growth of vaccines market.
• Product Development/Innovation: Detailed insights on newly launched products of the vaccines market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the vaccines market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccines market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark).
Table of Contents
1 INTRODUCTION 51
1.1 STUDY OBJECTIVES 51
1.2 MARKET DEFINITION 51
1.2.1 INCLUSIONS AND EXCLUSIONS 52
1.3 MARKET SCOPE 53
1.3.1 MARKETS COVERED 53
1.3.2 REGIONS COVERED 53
1.3.3 YEARS CONSIDERED 54
1.3.4 CURRENCY CONSIDERED 54
1.4 STAKEHOLDERS 54
1.5 SUMMARY OF CHANGES 55
1.5.1 RECESSION IMPACT 55
2 RESEARCH METHODOLOGY 56
2.1 RESEARCH DATA 56
2.2 RESEARCH APPROACH 56
FIGURE 1 RESEARCH DESIGN 56
2.2.1 SECONDARY DATA 57
2.2.2 PRIMARY DATA 58
FIGURE 2 BREAKDOWN OF PRIMARIES 58
2.2.2.1 Primary research 58
2.3 MARKET SIZE ESTIMATION 59
FIGURE 3 MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023 59
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023 60
FIGURE 5 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS, 2023 60
2.3.1 INSIGHTS FROM PRIMARIES 62
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 62
2.3.2 SEGMENTAL ASSESSMENT 62
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 62
2.4 GROWTH RATE ASSUMPTIONS 64
FIGURE 8 VACCINES MARKET: CAGR PROJECTION (2024-2029) 64
FIGURE 9 VACCINES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 65
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 66
FIGURE 10 DATA TRIANGULATION METHODOLOGY 66
2.6 STUDY ASSUMPTIONS 67
2.7 RESEARCH LIMITATIONS 67
2.8 RISK ASSESSMENT 67
2.9 RECESSION IMPACT ANALYSIS 68
3 EXECUTIVE SUMMARY 69
FIGURE 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 69
FIGURE 12 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 70
FIGURE 13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION) 71
FIGURE 14 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION) 72
FIGURE 15 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION) 73
FIGURE 16 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION) 74
FIGURE 17 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION) 75
FIGURE 18 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION) 76
FIGURE 19 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION) 77
FIGURE 20 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION) 78
FIGURE 21 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (EXCLUDING COVID-19 VACCINES) 79
FIGURE 22 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (INCLUDING COVID-19 VACCINES) 80
4 PREMIUM INSIGHTS 81
4.1 VACCINES MARKET OVERVIEW (INCLUDING COVID-19 VACCINES) 81
FIGURE 23 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 81
4.2 VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES) 82
FIGURE 24 LAUNCH OF RSV VACCINES AND STRONG PRODUCT PIPELINE TO DRIVE MARKET 82
4.3 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY AND COUNTRY, 2023 83
FIGURE 25 US AND CONJUGATE VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2023 83
4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET (EXCLUDING COVID-19 VACCINES) 84
FIGURE 26 ASIA PACIFIC MARKETS TO REGISTER HIGHEST GROWTH RATES DURING FORECAST PERIOD 84
5 MARKET OVERVIEW 85
5.1 INTRODUCTION 85
5.2 MARKET DYNAMICS 85
FIGURE 27 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET 85
TABLE 1 IMPACT ANALYSIS: VACCINES MARKET 86
5.2.1 DRIVERS 86
5.2.1.1 Focus on vaccine development and launches 86
5.2.1.2 Rising prevalence of infectious diseases 87
FIGURE 28 US: INCIDENCE OF TUBERCULOSIS, 2017–2021 88
5.2.1.3 Increasing immunization programs 88
5.2.1.4 Advancements in vaccine technology 89
5.2.1.5 Government support and funding for vaccine development 89
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION) 90
5.2.2 RESTRAINTS 90
5.2.2.1 High cost of vaccine development 90
5.2.3 OPPORTUNITIES 91
5.2.3.1 Rising focus on therapeutic vaccines 91
5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials 91
5.2.4 CHALLENGES 92
5.2.4.1 Stringent regulatory processes 92
5.2.4.2 Product recalls 92
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
FIGURE 29 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS 93
5.4 PRICING ANALYSIS 93
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER 93
TABLE 3 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES 93
TABLE 4 AVERAGE SELLING PRICE OF ADULT VACCINES 95
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE 96
TABLE 5 AVERAGE SELLING PRICE OF CONJUGATE VACCINES 96
TABLE 6 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES 96
TABLE 7 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES 97
TABLE 8 AVERAGE SELLING PRICE OF LIVE ATTENUATED VACCINES 97
TABLE 9 AVERAGE SELLING PRICE OF TOXOID VACCINES 98
TABLE 10 AVERAGE SELLING PRICE OF M-RNA VACCINES 98
5.4.3 AVERAGE SELLING PRICE TREND 99
5.5 TECHNOLOGY ANALYSIS 99
5.5.1 MRNA VACCINES 99
5.5.2 DNA TECHNOLOGY 99
5.5.3 VLP VACCINE TECHNOLOGY 99
5.6 VALUE CHAIN ANALYSIS 100
FIGURE 30 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE 100
5.7 PIPELINE ANALYSIS 101
FIGURE 31 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 101
FIGURE 32 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 101
TABLE 11 PIPELINE PRODUCTS UNDER PHASE 2 AND PHASE 3 CLINICAL TRIALS 102
TABLE 12 VACCINE PIPELINE PRODUCTS UNDER PHASE-3 CLINICAL TRIALS FOR RSV 105
5.7.1 KEY PIPELINE PRODUCTS 112
TABLE 13 KEY PIPELINE VACCINES: GSK PLC 112
TABLE 14 KEY PIPELINE VACCINES: MERCK & CO., INC. 112
TABLE 15 KEY PIPELINE VACCINES: PFIZER INC. 112
TABLE 16 KEY PIPELINE VACCINES: SANOFI S.A. 112
5.8 ECOSYSTEM/MARKET MAP 113
FIGURE 33 ECOSYSTEM/MARKET MAP 113
TABLE 17 ROLE IN ECOSYSTEM: VACCINES MARKET 113
5.9 REGULATORY ANALYSIS 114
TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114
TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117
TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117
TABLE 22 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118
TABLE 23 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118
5.10 PORTER’S FIVE FORCES ANALYSIS 118
TABLE 24 PORTER’S FIVE FORCES ANALYSIS 118
5.10.1 THREAT OF NEW ENTRANTS 119
5.10.2 THREAT OF SUBSTITUTES 119
5.10.3 BARGAINING POWER OF SUPPLIERS 119
5.10.4 BARGAINING POWER OF BUYERS 119
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 119
5.11 PATENT ANALYSIS 120
FIGURE 34 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023 120
TABLE 25 VACCINES MARKET: INDICATIVE LIST OF PATENTS 121
5.12 KEY CONFERENCES & EVENTS, 2024–2025 122
TABLE 26 DETAILED LIST OF CONFERENCES & EVENTS 122
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 123
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 123
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 123
5.13.2 KEY BUYING CRITERIA 123
FIGURE 36 KEY BUYING CRITERIA FOR END USERS 123
6 VACCINES MARKET, BY TECHNOLOGY 124
6.1 INTRODUCTION 125
TABLE 27 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 125
TABLE 28 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 126
6.2 CONJUGATE VACCINES 126
6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET 126
TABLE 29 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 127
TABLE 30 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 31 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 32 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 33 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 129
6.3 RECOMBINANT VACCINES 130
6.3.1 LOW POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET 130
TABLE 34 EXAMPLES OF RECOMBINANT VACCINES 130
TABLE 35 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 131
TABLE 36 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 37 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 38 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 39 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 133
6.4 INACTIVATED & SUBUNIT VACCINES 133
6.4.1 EASE OF STORAGE AND TRANSPORTATION TO SUPPORT GROWTH 133
TABLE 40 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 134
TABLE 41 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 135
TABLE 42 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 43 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 44 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 45 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 137
6.5 LIVE ATTENUATED VACCINES 137
6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO RESTRAIN MARKET 137
TABLE 46 EXAMPLES OF LIVE ATTENUATED VACCINES 138
TABLE 47 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 138
TABLE 48 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 49 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 50 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 51 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 140
6.6 TOXOID VACCINES 141
6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET 141
TABLE 52 EXAMPLES OF TOXOID VACCINES 141
TABLE 53 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 142
TABLE 54 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 55 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 56 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 57 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 144
6.7 VIRAL VECTOR VACCINES 144
6.7.1 RISING INVESTMENT IN VACCINE DEVELOPMENT TO DRIVE MARKET 144
TABLE 58 VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 145
TABLE 59 NORTH AMERICA: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 60 EUROPE: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 61 ASIA PACIFIC: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 62 LATIN AMERICA: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 147
6.8 MRNA VACCINES 147
6.8.1 INCREASING FOCUS ON MRNA VACCINE DEVELOPMENT TO DRIVE MARKET 147
TABLE 63 MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 148
TABLE 64 NORTH AMERICA: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 65 EUROPE: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 66 ASIA PACIFIC: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 67 LATIN AMERICA: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 150
6.9 OTHER VACCINES 151
TABLE 68 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 151
TABLE 69 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 70 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 71 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 72 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 153
7 VACCINES MARKET, BY TYPE 154
7.1 INTRODUCTION 155
TABLE 73 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 155
TABLE 74 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 156
7.2 MULTIVALENT VACCINES 156
7.2.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET 156
TABLE 75 EXAMPLES OF MULTIVALENT VACCINES 157
TABLE 76 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 158
TABLE 77 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 78 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 79 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 80 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 160
7.3 MONOVALENT VACCINES 160
7.3.1 RISING R&D INVESTMENTS AND PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 160
TABLE 81 EXAMPLES OF MONOVALENT VACCINES 161
TABLE 82 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 162
TABLE 83 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 84 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 85 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 86 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 164
8 VACCINES MARKET, BY DISEASE INDICATION 165
8.1 INTRODUCTION 166
TABLE 87 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 166
TABLE 88 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 167
8.2 PNEUMOCOCCAL DISEASE 167
8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET 167
TABLE 89 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 168
TABLE 90 PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 169
TABLE 91 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 92 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 93 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 94 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 171
8.3 INFLUENZA 171
8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET 171
TABLE 95 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 172
TABLE 96 INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 173
TABLE 97 NORTH AMERICA: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 98 EUROPE: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 99 ASIA PACIFIC: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 100 LATIN AMERICA: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 175
8.4 COMBINATION VACCINES 175
8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET 175
TABLE 101 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 176
TABLE 102 COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 177
TABLE 103 NORTH AMERICA: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 104 EUROPE: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 105 ASIA PACIFIC: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 106 LATIN AMERICA: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 179
8.5 HPV 179
8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET 179
TABLE 107 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 180
TABLE 108 HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 181
TABLE 109 NORTH AMERICA: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 110 EUROPE: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 111 ASIA PACIFIC: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 112 LATIN AMERICA: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 183
8.6 MENINGOCOCCAL DISEASE 183
8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET 183
TABLE 113 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 184
TABLE 114 MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 184
TABLE 115 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 116 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 117 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 118 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 186
8.7 HERPES ZOSTER 187
8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 187
TABLE 119 HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 188
TABLE 120 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 121 EUROPE: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 122 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 123 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 190
8.8 ROTAVIRUS 190
8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO PROPEL MARKET 190
TABLE 124 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 191
TABLE 125 ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 191
TABLE 126 NORTH AMERICA: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 127 EUROPE: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 128 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 129 LATIN AMERICA: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 193
8.9 MMR 194
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO BOOST DEMAND 194
TABLE 130 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 194
TABLE 131 MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 195
TABLE 132 NORTH AMERICA: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 133 EUROPE: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 134 ASIA PACIFIC: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 135 LATIN AMERICA: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 197
8.10 VARICELLA 197
8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH 197
TABLE 136 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 197
TABLE 137 VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 198
TABLE 138 NORTH AMERICA: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 139 EUROPE: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 140 ASIA PACIFIC: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 141 LATIN AMERICA: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 200
8.11 HEPATITIS 200
8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET 200
TABLE 142 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 201
TABLE 143 HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 201
TABLE 144 NORTH AMERICA: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 145 EUROPE: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 146 ASIA PACIFIC: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 147 LATIN AMERICA: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 203
8.12 DTP 204
8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET 204
TABLE 148 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 204
TABLE 149 DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 205
TABLE 150 NORTH AMERICA: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 151 EUROPE: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 152 ASIA PACIFIC: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 153 LATIN AMERICA: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 207
8.13 POLIO 207
8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET 207
TABLE 154 POLIO VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 208
TABLE 155 NORTH AMERICA: POLIO VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 156 EUROPE: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 157 ASIA PACIFIC: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 210
TABLE 158 LATIN AMERICA: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 210
8.14 RSV 211
8.14.1 STRONG PRODUCT PIPELINE AND NEW PRODUCT LAUNCHES TO PROPEL MARKET GROWTH 211
TABLE 159 RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 212
TABLE 160 NORTH AMERICA: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 161 EUROPE: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 162 ASIA PACIFIC: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 163 LATIN AMERICA: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 214
8.15 OTHER DISEASE INDICATIONS 214
FIGURE 37 US: NUMBER OF COVID-19 CASES, 2020–2023 215
TABLE 164 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 215
TABLE 165 VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 216
TABLE 166 VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 216
TABLE 167 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 217
TABLE 168 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 217
TABLE 169 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 170 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 171 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 172 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 173 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 220
TABLE 174 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 220
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 221
9.1 INTRODUCTION 222
TABLE 175 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), 2022–2029 (USD MILLION) 222
TABLE 176 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (INCLUDING COVID-19 VACCINES), 2022–2029 (USD MILLION) 223
9.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 223
9.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION 223
TABLE 177 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 224
TABLE 178 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 225
TABLE 179 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 225
TABLE 180 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 181 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 182 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 227
9.3 ORAL ADMINISTRATION 227
9.3.1 REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE ADOPTION 227
TABLE 183 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 228
TABLE 184 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 228
TABLE 185 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 229
TABLE 186 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 229
TABLE 187 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 230
9.4 OTHER ROUTES OF ADMINISTRATION 230
TABLE 188 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 231
TABLE 189 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 231
TABLE 190 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 232
TABLE 191 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 232
TABLE 192 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 233
10 VACCINES MARKET, BY END USER 234
10.1 INTRODUCTION 235
TABLE 193 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 235
TABLE 194 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 235
10.2 ADULT VACCINES 236
10.2.1 ADULT VACCINES TO COMMAND LARGER MARKET SHARE 236
TABLE 195 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 237
TABLE 196 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 237
TABLE 197 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 238
TABLE 198 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 238
TABLE 199 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 239
10.3 PEDIATRIC VACCINES 239
10.3.1 SUPPORT FROM GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET 239
TABLE 200 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 240
TABLE 201 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 240
TABLE 202 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 241
TABLE 203 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 241
TABLE 204 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 242
11 VACCINES MARKET, BY REGION 243
11.1 INTRODUCTION 244
TABLE 205 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 244
TABLE 206 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION) 245
11.2 NORTH AMERICA 245
11.2.1 NORTH AMERICA: RECESSION IMPACT 245
FIGURE 38 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 246
TABLE 207 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 247
TABLE 208 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 247
TABLE 209 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 210 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 249
TABLE 211 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 250
TABLE 212 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 250
11.2.2 US 251
11.2.2.1 US to dominate North American market 251
TABLE 213 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 252
TABLE 214 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 215 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 253
TABLE 216 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 254
TABLE 217 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 254
11.2.3 CANADA 254
11.2.3.1 High incidence of infectious diseases to drive market 254
TABLE 218 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 255
TABLE 219 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 220 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 256
TABLE 221 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 257
TABLE 222 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 257
11.3 EUROPE 258
11.3.1 EUROPE: RECESSION IMPACT 258
TABLE 223 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 258
TABLE 224 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 259
TABLE 225 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 226 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 260
TABLE 227 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 261
TABLE 228 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 261
11.3.2 GERMANY 262
11.3.2.1 Significant R&D investments and growing biotechnology industry to drive market 262
TABLE 229 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 263
TABLE 230 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 263
TABLE 231 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 264
TABLE 232 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 264
11.3.3 UK 264
11.3.3.1 Launch of new products and increased funding by government and non-government organizations to drive market 264
TABLE 233 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 265
TABLE 234 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 235 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 266
TABLE 236 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 267
11.3.4 FRANCE 267
11.3.4.1 Favorable government initiatives for mass immunization to drive market 267
TABLE 237 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 268
TABLE 238 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 239 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 269
TABLE 240 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 269
11.3.5 ITALY 269
11.3.5.1 Higher investments by companies for increased production capacities to drive market 269
TABLE 241 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 270
TABLE 242 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 270
TABLE 243 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 271
TABLE 244 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 271
11.3.6 SPAIN 271
11.3.6.1 Rising investments in vaccine development by private organizations to drive market 271
TABLE 245 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 272
TABLE 246 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 247 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 273
TABLE 248 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 273
11.3.7 REST OF EUROPE 273
TABLE 249 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 274
TABLE 250 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 275
TABLE 251 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 275
TABLE 252 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 276
11.4 ASIA PACIFIC 276
11.4.1 ASIA PACIFIC: RECESSION IMPACT 277
FIGURE 39 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 278
TABLE 253 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 279
TABLE 254 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 279
TABLE 255 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 280
TABLE 256 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 280
TABLE 257 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 281
TABLE 258 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 281
11.4.2 JAPAN 282
11.4.2.1 Favorable government initiatives to support market growth 282
TABLE 259 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 282
TABLE 260 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 261 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 283
TABLE 262 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 284
11.4.3 SOUTH KOREA 284
11.4.3.1 Strong government strategies for improved vaccine hubs to drive market 284
TABLE 263 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 285
TABLE 264 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 265 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 286
TABLE 266 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 286
11.4.4 CHINA 286
11.4.4.1 China to hold largest share in APAC vaccines market 286
TABLE 267 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 287
TABLE 268 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 287
TABLE 269 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 288
TABLE 270 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 288
11.4.5 INDIA 289
11.4.5.1 Increasing government initiatives and development of new and improved vaccines to drive market 289
TABLE 271 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 289
TABLE 272 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 290
TABLE 273 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 290
TABLE 274 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 291
11.4.6 REST OF ASIA PACIFIC 291
TABLE 275 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 292
TABLE 276 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 277 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 293
TABLE 278 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 293
11.5 LATIN AMERICA 294
11.5.1 LATIN AMERICA: RECESSION IMPACT 294
TABLE 279 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION) 294
TABLE 280 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 295
TABLE 281 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 295
TABLE 282 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 296
TABLE 283 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 297
TABLE 284 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 297
11.5.2 BRAZIL 297
11.5.2.1 Rising focus on immunization programs to drive market 297
TABLE 285 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 298
TABLE 286 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 298
TABLE 287 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 299
TABLE 288 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 299
11.5.3 MEXICO 299
11.5.3.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth 299
TABLE 289 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 300
TABLE 290 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 291 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 301
TABLE 292 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 301
11.5.4 REST OF LATIN AMERICA 301
TABLE 293 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 302
TABLE 294 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 302
TABLE 295 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 303
TABLE 296 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 303
11.6 MIDDLE EAST & AFRICA 304
11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 304
11.6.2 MIDDLE EAST 304
11.6.2.1 Increasing prevalence of infectious diseases to drive market 304
TABLE 297 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 304
TABLE 298 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 305
TABLE 299 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION) 305
TABLE 300 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 306
TABLE 301 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 306
11.6.3 AFRICA 306
11.6.3.1 Availability of funds and grants from developed economies to drive market 306
TABLE 302 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION) 307
TABLE 303 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION) 307
TABLE 304 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 308
TABLE 305 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION) 308
12 COMPETITIVE LANDSCAPE 309
12.1 INTRODUCTION 309
12.2 KEY STRATEGIES/RIGHT TO WIN 309
FIGURE 40 STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET 310
12.3 REVENUE SHARE ANALYSIS 311
FIGURE 41 REVENUE SHARE ANALYSIS, 2021–2023 311
12.4 MARKET SHARE ANALYSIS 311
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 312
TABLE 306 VACCINES MARKET: DEGREE OF COMPETITION 312
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 313
12.5.1 STARS 313
12.5.2 EMERGING LEADERS 314
12.5.3 PERVASIVE PLAYERS 314
12.5.4 PARTICIPANTS 314
FIGURE 43 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 315
12.5.5 COMPANY FOOTPRINT 316
TABLE 307 TYPE FOOTPRINT 316
TABLE 308 REGIONAL FOOTPRINT 317
12.6 COMPANY EVALUATION MATRIX: START-UP/SME PLAYERS 318
12.6.1 PROGRESSIVE COMPANIES 318
12.6.2 RESPONSIVE COMPANIES 318
12.6.3 DYNAMIC COMPANIES 318
12.6.4 STARTING BLOCKS 318
FIGURE 44 VACCINES MARKET: COMPANY EVALUATION MATRIX (START-UP/SME PLAYERS), 2023 319
12.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES 320
TABLE 309 VACCINES MARKET: DETAILED LIST OF KEY START-UPS/SMES 320
TABLE 310 VACCINES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES 321
12.7 COMPETITIVE SCENARIOS 322
12.7.1 PRODUCT LAUNCHES & APPROVALS 322
TABLE 311 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021−APRIL 2024) 322
12.7.2 DEALS 323
TABLE 312 VACCINES MARKET: DEALS (JANUARY 2021−APRIL 2024) 323
12.7.3 EXPANSIONS 324
TABLE 313 VACCINES MARKET: EXPANSIONS (JANUARY 2021−APRIL 2024) 324
12.7.4 OTHER DEVELOPMENTS 324
TABLE 314 VACCINES MARKET: OTHER DEVELOPMENTS (JANUARY 2021−APRIL 2024) 324
13 COMPANY PROFILES 325
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
13.1 KEY PLAYERS 325
13.1.1 GSK PLC 325
TABLE 315 GSK PLC: COMPANY OVERVIEW 325
FIGURE 45 GSK PLC: COMPANY SNAPSHOT (2023) 326
TABLE 316 GSK PLC: PRODUCTS OFFERED 326
TABLE 317 GSK PLC: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–MARCH 2024) 329
TABLE 318 GSK PLC: DEALS (JANUARY 2020–MARCH 2024) 330
TABLE 319 GSK PLC: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 332
13.1.2 MERCK & CO., INC. 333
TABLE 320 MERCK & CO., INC.: COMPANY OVERVIEW 333
FIGURE 46 MERCK & CO., INC.: COMPANY SNAPSHOT (2023) 334
TABLE 321 MERCK & CO., INC.: PRODUCTS OFFERED 334
TABLE 322 MERCK & CO., INC.: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 336
TABLE 323 MERCK & CO., INC.: DEALS (JANUARY 2020–MARCH 2024) 337
TABLE 324 MERCK & CO., INC.: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 337
13.1.3 PFIZER INC. 339
TABLE 325 PFIZER INC.: COMPANY OVERVIEW 339
FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT (2023) 340
TABLE 326 PFIZER INC.: PRODUCTS OFFERED 340
TABLE 327 PFIZER INC.: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 341
TABLE 328 PFIZER INC.: DEALS (JANUARY 2020–MARCH 2024) 343
TABLE 329 PFIZER INC.: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 344
13.1.4 SANOFI 345
TABLE 330 SANOFI: COMPANY OVERVIEW 345
FIGURE 48 SANOFI: COMPANY SNAPSHOT (2023) 346
TABLE 331 SANOFI: PRODUCTS OFFERED 346
TABLE 332 SANOFI: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 347
TABLE 333 SANOFI: DEALS (JANUARY 2020–MARCH 2024) 348
TABLE 334 SANOFI: EXPANSIONS (JANUARY 2020–MARCH 2024) 349
TABLE 335 SANOFI: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 349
13.1.5 CSL 350
TABLE 336 CSL: COMPANY OVERVIEW 350
FIGURE 49 CSL: COMPANY SNAPSHOT (2023) 351
TABLE 337 CSL: PRODUCTS OFFERED 351
TABLE 338 CSL: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 352
TABLE 339 CSL: DEALS (JANUARY 2020–MARCH 2024) 352
TABLE 340 CSL: EXPANSIONS (JANUARY 2020–MARCH 2024) 353
TABLE 341 CSL: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 354
13.1.6 EMERGENT 355
TABLE 342 EMERGENT: COMPANY OVERVIEW 355
FIGURE 50 EMERGENT: COMPANY SNAPSHOT (2023) 356
TABLE 343 EMERGENT: PRODUCTS OFFERED 356
TABLE 344 EMERGENT: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 357
TABLE 345 EMERGENT: DEALS (JANUARY 2020–MARCH 2024) 358
TABLE 346 EMERGENT: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 358
13.1.7 JOHNSON & JOHNSON SERVICES, INC. 359
TABLE 347 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW 359
FIGURE 51 JOHNSON & JOHNSON SERVICES INC.: COMPANY SNAPSHOT (2023) 360
TABLE 348 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS OFFERED 360
TABLE 349 JOHNSON & JOHNSON SERVICES INC.: PRODUCT APPROVALS (JANUARY 2020− MARCH 2024) 361
TABLE 350 JOHNSON & JOHNSON SERVICES INC.: DEALS (JANUARY 2020–MARCH 2024) 361
13.1.8 ASTRAZENECA 362
TABLE 351 ASTRAZENECA: COMPANY OVERVIEW 362
FIGURE 52 ASTRAZENECA: COMPANY SNAPSHOT (2023) 363
TABLE 352 ASTRAZENECA: PRODUCTS OFFERED 363
TABLE 353 ASTRAZENECA: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 364
TABLE 354 ASTRAZENECA: DEALS (JANUARY 2020–MARCH 2024) 364
TABLE 355 ASTRAZENECA: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 365
13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD. 366
TABLE 356 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW 366
TABLE 357 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED OVERSEAS) 366
TABLE 358 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED IN INDIA) 368
TABLE 359 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS LAUNCHES & APPROVALS
TABLE 360 SERUM INSTITUTE OF INDIA PVT., LTD.: DEALS (JANUARY 2020–MARCH 2024) 371
13.1.10 BAVARIAN NORDIC 372
TABLE 361 BAVARIAN NORDIC: COMPANY OVERVIEW 372
FIGURE 53 BAVARIAN NORDIC: COMPANY SNAPSHOT (2023) 373
TABLE 362 BAVARIAN NORDIC: PRODUCTS OFFERED 373
TABLE 363 BAVARIAN NORDIC: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–MARCH 2024) 374
TABLE 364 BAVARIAN NORDIC: DEALS (JANUARY 2020–MARCH 2024) 374
TABLE 365 BAVARIAN NORDIC: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 376
13.1.11 MITSUBISHI TANABE PHARMA CORPORATION 377
TABLE 366 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW 377
TABLE 367 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCTS OFFERED 377
TABLE 368 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 378
TABLE 369 MITSUBISHI TANABE PHARMA CORPORATION: DEALS (JANUARY 2020–MARCH 2024) 378
13.1.12 DAIICHI SANKYO COMPANY, LIMITED 379
TABLE 370 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 379
FIGURE 54 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022) 380
TABLE 371 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED 380
TABLE 372 DAIICHI SANKYO COMPANY, LIMITED: DEALS (JANUARY 2020–MARCH 2024) 381
13.1.13 PANACEA BIOTEC 382
TABLE 373 PANACEA BIOTEC: COMPANY OVERVIEW 382
FIGURE 55 PANACEA BIOTEC: COMPANY SNAPSHOT (2022) 383
TABLE 374 PANACEA BIOTEC: PRODUCTS OFFERED 383
TABLE 375 PANACEA BIOTEC: DEALS (JANUARY 2020–MARCH 2024) 384
TABLE 376 PANACEA BIOTEC: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 384
13.1.14 BIOLOGICAL E LIMITED 385
TABLE 377 BIOLOGICAL E LIMITED: COMPANY OVERVIEW 385
TABLE 378 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INDIAN MARKET) 385
TABLE 379 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INTERNATIONAL MARKET) 386
TABLE 380 BIOLOGICAL E LIMITED: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 387
TABLE 381 BIOLOGICAL E LIMITED: DEALS (JANUARY 2020–MARCH 2024) 388
TABLE 382 BIOLOGICAL E LIMITED: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 388
13.1.15 BHARAT BIOTECH 389
TABLE 383 BHARAT BIOTECH: COMPANY OVERVIEW 389
TABLE 384 BHARAT BIOTECH: PRODUCTS OFFERED (VACCINES) 389
TABLE 385 BHARAT BIOTECH: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–MARCH 2024) 390
TABLE 386 BHARAT BIOTECH: DEALS (JANUARY 2020–MARCH 2024) 391
13.1.16 NOVAVAX 393
TABLE 387 NOVAVAX: COMPANY OVERVIEW 393
FIGURE 56 NOVAVAX: COMPANY SNAPSHOT (2023) 393
TABLE 388 NOVAVAX: PRODUCTS OFFERED (VACCINES) 394
TABLE 389 NOVAVAX: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024) 394
TABLE 390 NOVAVAX: DEALS (JANUARY 2020–MARCH 2024) 396
13.1.17 INOVIO PHARMACEUTICALS 397
TABLE 391 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW 397
FIGURE 57 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2023) 397
TABLE 392 INOVIO PHARMACEUTICALS: PRODUCTS OFFERED (VACCINES) 398
TABLE 393 INOVIO PHARMACEUTICALS: DEALS (JANUARY 2020–MARCH 2024) 398
TABLE 394 INOVIO PHARMACEUTICALS: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024) 399
13.2 OTHER PLAYERS 400
13.2.1 SINOVAC 400
13.2.2 INCEPTA PHARMACEUTICALS LTD. 401
13.2.3 VALNEVA SE 403
13.2.4 VBI VACCINE INC. 404
13.2.5 BIO FARMA 405
13.2.6 MICROGEN 407
13.2.7 ZHI FEI BIOLOGICAL 408
13.2.8 INDIAN IMMUNOLOGICALS LIMITED 409
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
14 APPENDIX 410
14.1 DISCUSSION GUIDE 410
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 414
14.3 CUSTOMIZATION OPTIONS 416
14.4 RELATED REPORTS 416
14.5 AUTHOR DETAILS 417